Raghu Chandramohan, Jacquelyn Reuther, Ilavarasi Gandhi, Horatiu Voicu, K. R. Alvarez, Kevin E. Fisher, D. Lopez-Terrada, D. W. Parsons, Angshumoy Roy
{"title":"Abstract 4233: Improving the diagnostic yield of a 124 gene pediatric solid tumor panel through somatic copy number variation analysis","authors":"Raghu Chandramohan, Jacquelyn Reuther, Ilavarasi Gandhi, Horatiu Voicu, K. R. Alvarez, Kevin E. Fisher, D. Lopez-Terrada, D. W. Parsons, Angshumoy Roy","doi":"10.1158/1538-7445.SABCS18-4233","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-4233","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117088931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Hua, D. Flowers, D. Kirouac, J. Burke, J. Apgar
{"title":"Abstract 678: Drug-induced TMDD: a novel class of PK models relevant to Immune-stimulating therapies","authors":"F. Hua, D. Flowers, D. Kirouac, J. Burke, J. Apgar","doi":"10.1158/1538-7445.AM2019-678","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-678","url":null,"abstract":"Purpose: Many biologics exhibit target-mediated drug disposition (TMDD). That is, given the high affinity and low doses typical for antibody-based therapeutics, drug clearance is often mediated through target binding and endocytosis, in addition to 1st-order elimination processes. Accounting for the process of TMDD in pharmacokinetic (PK) models is thus necessary to describe and predict drug exposure. TMDD is typically characterized by dose-dependent clearance, wherein drug elimination is faster at lower doses. In standard TMDD-models, target concentration and turnover are assumed to be constant. While this is generally a good approximation, the assumption does not always hold. Immune-stimulating drugs are the largest class of agents currently being developed in oncology, including checkpoint inhibitors (PD-1/PD-L1, CTLA4), cytokines (IL-2, IL-15), and immune agonists (GITR, OX40, ICOS). For immune-stimulating agents, drug treatment may induce lymphocyte proliferation, expanding the pool of target along with the target-expressing cells. TMDD in such cases is thus induced by drug treatment, and thereby target burden is dynamic; both dose- and time- dependent. PK dose response profiles in such cases could exhibit very different characteristics from standard (static) TMDD. Methods: The goal of this work is to invest the role of target dynamics on drug pharmacokinetics (PK) and receptor occupancy (RO). To do so, we have developed a mathematical modelling construct termed ‘Drug-induced TMDD’, wherein drug-target binding induces increase of the target synthesis rate, subsequently target concentration, leading to enhanced TMDD. We incorporate this construct into a 2-compartment model typical of monoclonal antibodies. Simulations were then used to characterize how dose, drug-target affinity, and the amplitude and the delay in target up-regulation affect the PK and RO profiles, and compared static vs. drug-induced TMDD behavior. Results: For Drug-induced TMDD, target expression increases with increased target engagement. This creates a pseudo-negative-feedback circuit, wherein the rate of TMDD-mediated clearance is dependent upon drug concentration. As a result, drug clearance does not appear dose-proportional at low doses, as is typical of static-TMDD. The AUC of drug concentration for drug-induced TMDD can be higher than static TMDD at low doses, but lower at higher doses. Similar results are predicted for the AUC of RO as well with the nominal parameter set. Increasing target affinity (decreasing KD) however results in faster clearance, typical of both cases of TMDD. Conclusions: Dynamic-TMDD could lead to different dose-dependent PK and RO behaviors from a static TMDD. Based on these characteristic profiles presented, one can determine whether a static vs. drug-induced TMDD model may be required for PK modelling, particularly important consideration for immune-stimulating biologics. Citation Format: Fei Hua, David Flowers, Daniel C. Kirouac, John M. B","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117342724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyeongi Kim, Yangjin Kim, Yong-Jin Lee, Jin Su Kim
{"title":"Abstract LB-219: Derivation of mathematical modeling for the diffusion and penetration of monoclonal antibody delivery into tumor","authors":"Hyeongi Kim, Yangjin Kim, Yong-Jin Lee, Jin Su Kim","doi":"10.1158/1538-7445.AM2019-LB-219","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-LB-219","url":null,"abstract":"Background: Commonly malignant solid tumor have an abundant tumor-associated cellular matrix (ECM). Although radioimmunothrepy (RIT) have proven to be effective and precise treatment in cancer, yet RIT has a limited performance in solid tumor, due to highly distributed ECM inside solid tumor tissue. Previously, we designed the combination RIT to enhance the penetration of monoclonal antibody (mAb), where we investigated that, using Relaxin which contain oncolytic adenovirus (OA) as combination therapy decreases tumor associated ECM. In this study, we developed mathematical modeling to explain and describe the diffusion and penetration of mAb inside the tumor with ECM. To obtain the model parameters in our developed mathematical model, we performed related experiments such as immunofluorescence and qRT-PCR. Methods: We developed the reaction-diffusion partial differential equations (PDE) for describing the dependency of cancer cell, ECM density, diffusion and penetration of mAb and ECM modulated therapy that include our experimental data, also to overcome the classical limitation of PDE method. Model included the rapid decrease of ECM by OA, and density dependent diffusion coefficient. Initial condition for solving the PDE was derived using our experimental result. Diffusion coefficient for mAb and OA was modelled for simulating actual behavior of mAb and OA. Various condition of ECM density, and structure were modelled that derives the actual result of distribution of collagen. To confirm the mathematical prediction, we designed in vitro experiment with same condition as used as “in model”. Results: Using our developed model, we successfully described relationship between ECM and mAb transport by OA, and investigated the change of ECM. Diffusion and penetration of mAb and OA were well described from tumor vessel and tumor surface. Regardless of ECM structure, all ECM structure were degraded after spreading of OA. In addition, our model simulation results predicted that mAb uptake dramatically increased in combination approach and was more than mAb alone treatment. Our developed mathematical model predicted the optimal schedule of OA pretreatment and it shows great results more than mAb pretreatment. Pretreatment results with OA shows a great anti-tumor effect more than mAb pretreatment in experimental data. Our model could well predicted and matched the experimental results. Collectively, in our study, we suggested new theoretical mathematical model framework to explain various ECM condition with drug transport Citation Format: Hyeongi Kim, Yangjin Kim, Yong-Jin Lee, Jin-su Kim. Derivation of mathematical modeling for the diffusion and penetration of monoclonal antibody delivery into tumor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-219.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"67 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121123056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Conte, J. Mason, Csaba Halmagyi, Abayomi Mosaku, S. Neuhauser, D. Begley, D. Krupke, H. Parkinson, T. Meehan, C. Bult
{"title":"Abstract 2461: PDX Finder: A free and global catalog of patient tumor derived xenograft models","authors":"N. Conte, J. Mason, Csaba Halmagyi, Abayomi Mosaku, S. Neuhauser, D. Begley, D. Krupke, H. Parkinson, T. Meehan, C. Bult","doi":"10.1158/1538-7445.SABCS18-2461","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2461","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129738362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kelsy C. Cotto, Yang-Yang Feng, Zachary L. Skidmore, O. Griffith, M. Griffith
{"title":"Abstract 2487: Application of RegTools to TCGA samples for the identification of tumor-specific splice variants","authors":"Kelsy C. Cotto, Yang-Yang Feng, Zachary L. Skidmore, O. Griffith, M. Griffith","doi":"10.1158/1538-7445.AM2019-2487","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-2487","url":null,"abstract":"The interpretation of variants in cancer is frequently focused on direct protein coding alterations. However, this analysis strategy excludes somatic mutations in non-coding regions of the genome and even exonic mutations may have unidentified non-coding consequences. To address this issue, we created RegTools (Feng et al. 2018), a free, open-source software package that integrates analysis of somatic variant calls from genomic data with splice junctions extracted from transcriptomic data in order to efficiently identify variants that may cause aberrant splicing in tumors. Initially, this software was developed using 188 cancer samples from 4 cancer types and enabled us to identify important non-coding variants which would otherwise be undervalued or perhaps even completely ignored by traditional methods and annotators. Here, we present the application of RegTools to over 10,000 TCGA samples in an effort to identify somatic variants that are associated with alternative splicing patterns within these tumors. In order to perform this analysis, we obtained all tumor samples that had somatic variant VCF files and RNA-seq bam files from the Genomic Data Commons (GDC). Included within these samples are more than 700 solid tissue normal samples, which will be used as a panel of normals in order to filter out variants and splicing events that are not tumor specific. We plan to present on the significance of our findings when analyzing these samples within their respective tumor type and across all tumor types. We also plan to present on whether these aberrant splicing events that result from somatic mutations might interfere with predicted neoantigens pVAC-Seq (Hundal et al. 2016). RegTools is freely available and open source (www.regtools.org). Citation Format: Kelsy C. Cotto, Yang-Yang Feng, Zachary L. Skidmore, Obi L. Griffith, Malachi Griffith. Application of RegTools to TCGA samples for the identification of tumor-specific splice variants [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2487.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128463675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yaohua Yang, Q. Cai, Lang Wu, X. Shu, Xingyi Guo, Ran Tao, Bingshan Li, X. Shu, W. Zheng, J. Long
{"title":"Abstract 1649: Integrating genome, transcriptome and methylome data to identify novel genes for lung cancer: Data from over 50,000 European participants","authors":"Yaohua Yang, Q. Cai, Lang Wu, X. Shu, Xingyi Guo, Ran Tao, Bingshan Li, X. Shu, W. Zheng, J. Long","doi":"10.1158/1538-7445.SABCS18-1649","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1649","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128718150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Ronen, Christopher M. DeBoever, Boguslaw Kluge, Janusz Dutkowski
{"title":"Abstract LB-217: The cancer subtype ontology: Predicting response to therapy in clinical and translational research using 840 cancer subtypes","authors":"R. Ronen, Christopher M. DeBoever, Boguslaw Kluge, Janusz Dutkowski","doi":"10.1158/1538-7445.SABCS18-LB-217","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-LB-217","url":null,"abstract":"Background: Detailed understanding of cancer subtypes is key to precision oncology and instrumental for effective patient-to-therapy assignment and development of combination therapy regimens. While many molecular and pathologic cancer subtypes have been developed over the last decade, key challenges remain. Paramount among them is the ability to effectively track and compare cancer subtypes across studies, identify meaningful associations with clinical outcomes, and robustly assign new patients into subtypes in a clinical setting. Approach: Here we report on the development of the Cancer Subtype Ontology (CSO) - a global resource for cancer subtype interrogation and patient-to-subtype assignment, constituting, to our knowledge, the largest collection of cancer subtypes to date. The foundational CSO resource currently catalogues 840 cancer subtypes which subcategorize ~40 histologies based on a diverse range of evidence types ranging from cancer genomics and transcriptomics, to epigenetics, proteomics and immune infiltration. CSO includes a wide collection of previously-published subtypes as well as a new model-based subtype collection reported here for the first time. CSO provides tools to compare across subtypes as well as characterize subtype enrichment for molecular, pathologic and clinical features, including response to therapy and patient survival. As an integrative part of the CSO, we develop a novel machine learning framework for robust assignment of new clinical and pre-clinical samples into the CSO subtypes. We first evaluate the CSO subtype collection using TCGA, measuring the ability to predict overall, progression-free, disease-specific, and disease-free survival. Next, using a novel curated collection of recent immune checkpoint inhibitor (ICI) trials, we demonstrate the power of the subtypes to predict ICI treatment responses and clinical outcomes. Results: First using TCGA, we found that the CSO significantly expands the ability to uncover subtypes predictive of clinical outcomes. Notably, new model-based subtypes in CSO, while constituting less than 1/3 of the ontology, accounted for ~60% of the most significant outcome associations across genomic and molecular subtypings. Next, we applied the CSO patient assignment system to systematically assign patients from 10 ICI trials across 4 histologies into 103 CSO subtypes. We found that half of the trials had CSO assignments predictive of patient survival and/or response and most of them were novel. Specifically, assignment of IMvigor 210 urinary bladder cancer patients revealed two subtypes enriched for partial (P=0.0002, OR=3.87) and complete response (P =0.002, OR=6.86), respectively, only one of which was previously characterized (Mariathasan et al. 2018). For the Snyder et al. 2014 cohort we observed that while stratification using the cohort data alone did not yield predictive subtypes, CSO patient assignment revealed subtypes that were predictive of long term clinical benefit ","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"117 5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130401955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James E. Shima, James L. Chen, M. Glick, Ryan A. Warrier, Eric C. Abruzzese, W. Mankowski, J. Hirsch
{"title":"Abstract 1676: A hybrid ontology and graph system enabling precision oncology applications through real-time incorporation of omics biomarkers into a scalable real-world data platform","authors":"James E. Shima, James L. Chen, M. Glick, Ryan A. Warrier, Eric C. Abruzzese, W. Mankowski, J. Hirsch","doi":"10.1158/1538-7445.SABCS18-1676","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1676","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123653507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstract 5120: Managing human tissues, bio-fluids, and clinical trial data at Fidelis Research leveraging a cloud-based system","authors":"Aditi Gade, Arun Apte, S. Paul, Iliyan Hristov","doi":"10.1158/1538-7445.AM2019-5120","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-5120","url":null,"abstract":"Introduction: Founded in 2012, Fidelis Research provides high-quality human tissues and bio-fluids specimens along with de-identified patient disease information to pharmaceutical, biotechnology, and pre-clinical contract research companies to facilitate their research. Fidelis has collection sites in South East Europe - Bulgaria, Romania, Croatia, Serbia, and Turkey. Through these sites, the company identifies patients, obtains consents, and then collects various types of samples. Additionally, the company has also established Clinical Research Units that conducts clinical trials. The primary goal of Fidelis Research is to provide its customers with integrated services ranging from pre-clinical to market authorization stage of product development. To achieve this, a Laboratory Information Management System (LIMS) was indispensable. Description: At any given point, Fidelis works on multiple collection projects for different clients, collecting samples from several subjects and sites. The samples are shipped to the biobank facilities. This requires excellent data management to ensure that the right data is associated with the right samples, thus facilitating their shipping to clients. The main challenges the company faced before implementing CloudLIMS’ solution had to do mainly with the amount of time spent on manually entering data, the difficulties with ensuring the accuracy of data and QC, risks of overlapping or deleting data by multiple users, inconsistency in data presentation and usability for reporting and billing purposes. Results: After deploying the cloud-based LIMS, Fidelis is now able to efficiently manage and store human tissues and bio-fluids specimens collected along with the donor information such as age, sex, diagnosis, date of surgery, medical history, etc. With a cloud-based system, sharing specimens’ data internally and externally has become much easier and hassle-free. Fidelis’ clients have benefited from more consistently presented data, accurate reports, and faster turnaround times. Fidelis has integrated its label generation and printing with CloudLIMS, benefiting the company and its clients. Conclusion: Cloud-based LIMS facilitates Fidelis Research in providing high-quality, ethically-sourced human biospecimens for the research and development needs of pharmaceutical, and biotechnology companies. Additionally, the LIMS also helps Fidelis Research to comply with the EU Directives, FDA regulations, and the applicable national laws and ensure data security. The improvements achieved in the company’s operations range from shorter turnaround times for processing samples storage, shipping, data management and billing, to facilitating auxiliary services such as label generation and printing. Citation Format: Aditi Gade, Arun Apte, Shonali Paul, Iliyan P. Hristov. Managing human tissues, bio-fluids, and clinical trial data at Fidelis Research leveraging a cloud-based system [abstract]. In: Proceedings of the American Association ","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124486080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstract 3380: Methylome analysis of non-alcoholic fatty liver disease-associated hepatocellular carcinoma reveals etiology-specic pathway perturbations","authors":"Qiong Wu","doi":"10.1158/1538-7445.SABCS18-3380","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-3380","url":null,"abstract":"Chronic hepatitis B infection (HBV) and non-alcoholic fatty liver disease (NAFLD) have been shown to induce aberrant DNA methylation that may contribute to the development of hepatocellular carcinoma (HCC), which is one of the most common liver cancers. Most previous studies on DNA methylation in HCC have focused on altered methylation at gene promoters and CpG islands/shores. However, it has been increasingly recognized that DNA methylation in other genomic regions, including distal enhancers and gene bodies, could also play important roles in gene regulation in cancers. In our whole-genome bisulfite sequencing (WGBS) analysis of 10 human HBV-associated tumors and 10 human NAFLD-associated tumors, methylation states at all CpG sites in the genome of HCC tumors are comprehensively studied. To see how the methylomes of these two groups of HCC samples are related to other liver-related normal and pathogenic samples, we collected published WGBS data for HCC tumor, tumor adjacent and normal liver samples. Global hypermethylation of NAFLD-HCC has been identified compared with HBV-HCC and differentially methylated regions in enhancer and gene body regions also have been detected. Different methylation patterns for HCC pathogenesis with different etiologies have been detected and may offer potentially more specific therapeutic targets. This project is supported by Collaborative Research Fund C4017-14G and the Focused Innovations Scheme 1907309. Citation Format: Qiong Wu. Methylome analysis of non-alcoholic fatty liver disease-associated hepatocellular carcinoma reveals etiology-specic pathway perturbations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3380.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127594299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}